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Abstract
Hantaviruses are the causative agents of haemorrhagic fever with renal syndrome (HFRS) in Eurasia and of hantavirus cardiopulmonary
syndrome (HCPS) in the Americas. The case fatality rate varies between different hantaviruses and can be up to 40%. At present, there is no
speciﬁc treatment available. The hantavirus pathogenesis is not well understood, but most likely, both virus-mediated and host-mediated
mechanisms are involved. The aim of the present study was to investigate the association among Puumala hantavirus (PUUV) viral RNA load,
humoral immune response and disease severity in patients with HFRS. We performed a study of 105 PUUV-infected patients that were
followed during the acute phase of disease and for up to 1–3 months later. Fifteen of the 105 patients (14%) were classiﬁed as having
moderate/severe disease. A low PUUV-speciﬁc IgG response (p <0.05) and also a higher white blood cell count (p <0.001) were
signiﬁcantly associated with more severe disease. The PUUV RNA was detected in a majority of patient plasma samples up to 9 days after
disease onset; however, PUUV RNA load or longevity of viraemia were not signiﬁcantly associated with disease severity. We conclude that
a low speciﬁc IgG response was associated with disease severity in patients with HFRS, whereas PUUV RNA load did not seem to affect the
severity of HFRS. Our results raise the possibility of passive immunotherapy as a useful treatment for hantavirus-infected patients.
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Introduction
Hantaviruses can cause two febrile diseases in humans: hae-
morrhagic feverwith renal syndrome (HFRS) in Europe andAsia,
and hantavirus cardiopulmonary syndrome (HCPS) in the
Americas. Humans are infected by inhalation of aerosolized
rodent excreta containing virus. Puumala virus (PUUV) is
endemic in Central andNorthern Europe and causes a relatively
mild form of HFRS, also known as Nephropathia Epidemica. The
most common symptoms of PUUV infection are fever, head-
ache, nausea, vomiting, myalgia, abdominal/back pain and visual
disturbances [1]. Themajority of patients also have signs of renal
failure and other important clinical features are mild haemor-
rhagic manifestations and respiratory symptoms [2]. Predictors
of severe renal impairment in hantavirus-infected patients
include high leucocyte counts at the time of admission [3,4].
To date, there is no approved speciﬁc treatment for
hantavirus-infected patients, instead supportive care is applied
[5,6]. Hantaviruses are believed to be non-cytopathic and the
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mechanisms behind the capillary leakage and haemorrhage are
poorly understood. Studies imply that the pathogenesis is
multifactorial and includes contributions from immune
responses, platelet dysfunction, dysregulation of the endothe-
lial cell barrier and genetic host factors [1,7,8]. Among immune
parameters, over-activation of CD8 T cells and natural killer
cells, and induction of cytokines are thought to play important
roles [9–12]. Previous studies of viraemia in HCPS and HFRS
suggest an association between initial high viral load of
Dobrava, Sin Nombre and Hantaan viruses, respectively, and
a more severe clinical outcome [13–16]. This association
implicates a potential direct role for the virus in pathogenesis
and interventions with antivirals as a possible therapy for
hantavirus-infected patients. However, contradictory results
have been reported from studies regarding antiviral treatment
of HFRS and HCPS patients and one theory is that Ribavirin
may have been given too late in the course of infection
[6,17,18]. More data regarding the duration of viraemia are
needed to determine the window of opportunity for antiviral
therapy. Another approach for speciﬁc treatment of hantavirus
infection may be administration of human neutralizing anti-
bodies. However, there are no published controlled clinical
trials of immunotherapy for hantavirus-infection. Studies on
humoral immune responses to hantavirus infection have
shown an association between low speciﬁc IgG antibody titres
and disease severity for HCPS patients, suggesting that a strong
IgG response to infection might be protective [19,20]. The
results on speciﬁc IgA and IgM responses are contradictory
regarding an association with disease severity in HCPS [19,20].
In HFRS caused by PUUV not only IgG but also IgA is known to
neutralize the virus [19–21].
In this study on 105 PUUV-infected patients we analysed the
duration of viraemia and the association between disease
severity and viral load, humoral immune response and different
laboratory parameters. Our results address the potential use
of speciﬁc treatment, i.e. antivirals and immunotherapy in
hantavirus-infected patients.
Methods
Study design and patient material
Patients with acute HFRS were included at the Clinic of
Infectious Diseases, Umea University Hospital. All patients
were serologically veriﬁed by immunoﬂuorescence assay for
PUUV-speciﬁc IgM and IgG. If only IgM was present in the ﬁrst
serum sample the patient diagnosis had to be conﬁrmed by
seroconversion of IgG in follow-up samples. In three patients
only IgG was present and the acute infection was veriﬁed by
RNA detection with PCR or through avidity testing of the IgG
antibodies [22]. Both hospitalized patients and outpatients
were followed with regards to symptoms and routine labora-
tory tests. Blood samples were drawn at ﬁrst contact with
healthcare and thereafter repeated sampling was performed
approximately every other day during the acute phase. The
patients were followed up after 1–3 months. Written and oral
informed consent was obtained from all patients and the study
was approved by the regional ethics committee of Umea
University, Umea, Sweden.
Criteria for severe illness
Patients who met two or more of the following criteria were
considered to have a moderate/severe illness: treated in the
intensive care unit, dialysis, radiologically veriﬁed thrombosis,
need for platelet transfusion, moderate/severe hypotension
(systolic blood pressure ≤ 90 mmHg and intravenous ﬂuid
treatment at any given time during hospitalization), and
bleeding of moderate/major importance; i.e. gastrointestinal
bleeding, macroscopic haematuria and metrorrhagia [23].
Real-time reverse transcription-PCR
RNA extraction and real-time reverse transcription-PCR were
performed as previously described [24]. Brieﬂy, the RNA was
reverse-transcribed followed by a real-time PCR with primers
and probe detecting the PUUV S-segment.
Immunoﬂuorescence
To detect PUUV-speciﬁc IgM, IgA and IgG serum antibodies,
an immunoﬂuorecence analysis was performed as previously
described [24]. Brieﬂy, patient serum was added to spot-slides
covered with ﬁxed Vero E6 cells infected with the local strain
PUUV Umea/hu. For IgM analysis, sera were pretreated with
Reumatoid factor-absorbent (Virion\Serion GmbH, W€urzburg,
Germany) to eliminate possible interference by rheumatoid
factor. Presence of PUUV-speciﬁc antibodies was determined
by use of ﬂuorescein-conjugated rabbit anti-human IgM, IgA
and IgG (F0317, F0204 and F202, respectively by DAKO A/S
Glostrup, Denmark). Sera were diluted to the end-point titre
(Fig. 1).
Statistical analysis
The clinical symptoms were described using percentages,
whereas laboratory ﬁndings were presented as medians and
range. Mann–Whitney U test was used to compare labora-
tory ﬁndings between patients with mild versus severe
illness.
Binary logistic regression was performed to analyse asso-
ciations with disease severity. Levels of PUUV RNA, PUUV-
speciﬁc antibody titres and white blood cell count (all ﬁrst
available samples) were investigated as predictors for disease
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severity. Associations of severe disease with age, sex and the
number of days after disease onset when samples were
collected were also investigated. A multivariate model was
constructed by ﬁrst conducting univariate logistic regression
analysis for each factor separately and then by including all
signiﬁcant predictive factors simultaneously in a model. The
same procedure was applied to ﬁnd predictors for airway
symptoms, need for oxygen treatment and bleeding manifes-
tations. All statistical analyses were performed using SPSS for
Windows version 18.0 (SPSS Inc., Chicago, IL, USA). Limit of
signiﬁcance was set at 0.05.
Results
Clinical characteristics and laboratory ﬁndings
Older patients (>50 years) had a signiﬁcantly higher number of
hospital days compared with younger patients (mean 5.7 and
2.8 days, respectively, p 0.045). No difference was found in the
hospitalization rate or time spent in hospital between the
sexes (p 0.662, p 0.204, respectively) in the study group. All
105 patients had signs of acute HFRS. There were no fatal
cases, but 15 of the 105 patients (14%) were deﬁned as having
moderate/severe illness (Table 1). Of all patients, 26% had one
or more symptoms from the lower respiratory tract and 12%
were given oxygen treatment because of desaturation. Five
(4.8%) patients were treated in the intensive care unit for
symptoms such as respiratory failure, anuria, thrombosis or
confusion/depression of consciousness.
A majority of the patients had thrombocytopenia (Tables 1
and 2) and almost one-third showed bleeding manifestations.
Epistaxis was most frequent, but also haematemesis, melaena,
visible haematuria, petechial rash and haematoma were noted.
Eight patients received platelet infusion, either for bleeding in
combination with fever, or as a prophylactic treatment because
of pronounced thrombocytopenia with platelet counts less than
20 9 109 to 30 9 109/L. Acute renal failure was seen in one-
third of the patients (deﬁned as a creatinine level more than four
times normal). One patient had haemodialysis during the
hospital stay for renal impairment and volume overload.
Serum creatinine peaked at around day 8 after symptom
debut (Fig. 1a). The minimum platelet count was noted in the
(a)
(b)
FIG. 1. Laboratory ﬁndings and viral RNA kinetics in 105 patients
with Puumala hantavirus (PUUV) infection. (a) C-reactive protein
(CRP), creatinine and platelet count presented during the ﬁrst 3 weeks
after disease onset. (b) The kinetics of PUUV RNA load in plasma
samples from patients with mild versus moderate/severe illness. The
ﬁgure represents mean values for each time interval and the error bars
are standard error of the mean (SEM). In total, 341 plasma samples
from the 105 patients were analysed. The proportions of samples from
patients with moderate/severe versus mild illness were: (0–3 days) 4
vs 16 samples, (4–7 days) 14 vs 92, (8–11 days) 21 vs 87, (12–15 days)
7 vs 30, (16–19 days) 6 vs 23, and (20–23 days) 0 vs 16.
TABLE 1. Demographics of the study population and clinical
symptoms
Characteristics
All patients
(n = 105)
Moderate/severe
illness (n = 15)
Age, mean and range 50 (40–63) 58 (43–73)
Gender, female/male (n) 56/49 8/7
Hospital care 72% 100%
Days of hospital care (mean and range) 4 (0–55) 12 (1–55)
Fever 98% 100%
Headache 74% 47%
Backache 51% 33%
Nausea/vomiting 51% 53%
Respiratory symptoms 41% 67%
Lower respiratory symptoms 26% 53%
Abdominal pains 35% 40%
Blurred vision 21% 33%
Renal impairment
(creatinine > normal range)
88% 87%
Renal impairment
(creatinine >4 times normal)
33% 60%
Haemorrhagic manifestations 28% 33%
Thrombocytopenia (<100 9 109/L) 71% 93%
Thrombocytopenia (<50 9 109/L) 34% 80%
Respiratory symptoms included all symptoms from both the upper and lower
respiratory tract. Lower respiratory tract symptoms were deﬁned as dyspnoea,
hypoxia and obstructivity. Creatinine levels reported in (lM) were used as a
marker for renal impairment, when described as over normal range or more than
four times normal for women and men, respectively.
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ﬁrst days after disease onset, whereas it normalized at the time
of maximum creatinine levels. C-reactive protein, a marker for
inﬂammation, reached maximum levels after a few days
(Fig. 1a) and lactate dehydrogenase, corresponding to tissue
damage, was also increased during the acute infection (data not
shown).
Kinetics of PUUV RNA load
Puumala virus RNA was detected in 90% of the patient samples
collected at day 0–3 after onset of disease (mean 1.17 9 105
PUUV RNA copies/mL) and in 81% of the patient samples
collected at day 4–7 (Fig. 1b). In most patients, PUUV RNA
was detected until day 9 after symptom debut. In total, 80% of
the patients had detectable RNA in at least one sample and the
RNA-negative patients had their ﬁrst sample drawn at a
signiﬁcantly later day (p <0.001) of disease compared with the
positive (mean day 10.3 and 5.4, respectively).
The humoral immune response upon acute infection
The ﬁrst available serum sample from all patients was analysed
for PUUV-speciﬁc IgM, IgA and IgG (Fig. 2); 93% were IgM
positive, 86% were IgA positive and 80% were IgG positive.
(Fig. 2a–c). Four patients were negative for all three types of
antibodies in their ﬁrst samples, they all had their ﬁrst sample
taken at day 1–3 and they all seroconverted in follow-up
samples. Seventeen patients were positive for IgM but negative
for IgG in their ﬁrst sample, they all seroconverted for IgG in
follow-up samples.
All samples analysed after day 5 of disease had detectable
IgA and IgG (Fig. 2b,c). Only three patients were IgG and IgA
positive but IgM negative (sampling days 2, 4 and 9). No patient
was positive for IgA exclusively.
Association between antibody response and viral load
There was a statistically signiﬁcant inverse association between
presence of PUUV-speciﬁc IgG and IgA antibodies and low
PUUV RNA load (p 0.014 and p 0.001, respectively). No such
association could be seen for IgM (see Supplementary material,
Figures SI and S2).
Associations with disease severity
Patients with moderate/severe illness had signiﬁcantly lower
platelets, higher creatinine, higher lactate dehydrogenase,
higher white blood cell counts and neutrophils compared
with patients with mild disease (Table 2).
Potential predictors for disease severity were investigated.
Univariate logistic regression revealed that high age, low
PUUV-speciﬁc IgG response and higher white blood cell count
were signiﬁcantly associated with moderate/severe disease
(Table 3). We further combined all signiﬁcant factors in a
multivariate analysis, which conﬁrmed that low PUUV-speciﬁc
IgG-titre and higher white blood cell count were signiﬁcantly
associated with moderate/severe disease, whereas age was not
(p 0.248; Table 3). The difference in IgG titres and WBC
counts observed between mild and moderate/severe illness is
also presented in Table 2 and in Supplementary material,
Figures S3 and S4. High viral load was not signiﬁcantly
associated with severe disease (p 0.53). Although there was
a tendency for higher viral load in patients with moderate/
severe illness 0–3 days after disease onset, it was not
signiﬁcantly associated with disease severity (Table 3). We
also investigated if long-lasting presence of PUUV RNA in
blood was associated with more severe disease. Of the
patients, 46% had at least one positive sample during the
second and third weeks of disease; however, long lasting
viraemia was not associated with severe disease (p 0.735
Pearson chi-squared test).
Airway symptoms and bleeding diathesis are frequent in
hantavirus-infected patients so these symptoms were evalu-
ated in the same multivariate model as the disease severity
classiﬁcation. Higher age (OR = 1.039, 95% CI = 1.008–1.071,
p 0.013), and a lower IgG titre (OR = 0.680, 95% CI = 0.471–
TABLE 2. Laboratory ﬁndings in association with disease severity
All patients (n = 105) Mild illness (n = 90) Moderate/severe illness (n = 15) p-value Normal range
Max. CRP (mg/L) 68 (11–254) 65 (11–236) 82 (29–254) 0.083 <3 mg/L
Min. platelets (109/L) 72 (12–397) 79 (19–397) 35 (12–182) <0.001 Females 165–387, Males 145–348
Max. WBC (109/L) 9.5 (4–50) 9.2 (4–22) 14.3 (8–50) <0.001 3.5–8.8
Max. neutrophils (109/L) 5.8 (2.8–18.3) 5.6 (2.8–13.1) 7.2 (5.3–18.3) <0.001 1.8–6.3
Max. lymphocytes (109/L) 2.1 (0.6–6.2) 2.1 (0.6–6.2) 2.6 (0.6–6.0) 0.927 1.0–3.5
Max. monocytes (109/L) 0.9 (0.4–3.2) 0.9 (0.4–2.4) 1.1 (0.4–3.2) 0.352 0.3–1.2
Max. creatinine (lM) 232 (60–1634) 222 (60–1548) 370 (136–1634) 0.01 Females 45–90, Males 60–105
Min. sodium (mM) 136 (107–146) 136 (121–146) 130 (113–144) 0.064 137–145
Max. potassium (mM) 4.4 (3.3–6.3) 4.5 (3.3–6.3) 4.4 (3.8–5.0) 0.346 3.6–4.6
Max. ALT (lkat/L) 1.2 (0.33–7.81) 1.2 (0.3–7.8) 1.2 (0.3–3.6) 0.797 Females <0.75, Males <1.1
Max. AST (lkat/L) 1.0 (0.35–4.45) 1.0 (0.35–4.5) 1.2 (0.6–3.5) 0.209 Females <0.6, Males <0.75
Max. LD (lkat/L) 5.6 (2.6–11.8) 5.4 (2.6–11.8) 7.0 (4.2–10.3) 0.008 <4.2
IgG titre 1:320 (neg–1:5120) 1:320 (neg–1:5120) 1:40 (neg–1:1280) 0.023
CRP, C-reactive protein; WBC, white blood cell count; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LD, lactate dehydrogenase.
Laboratory values were given as medians, range within parentheses. The p-value was calculated using Mann–Whitney U test.
The median IgG titre is presented as median and range. Negative samples represent titres <1 : 40.
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0.980, p 0.039) were signiﬁcantly associated with airway
symptoms. Similarly, higher age (OR = 1.10, 95%
CI = 1.035–1.167, p 0.002) and lower IgG titre (OR = 0.566,
95% CI = 0.330–0.970, p 0.038) were associated with the
need for oxygen treatment. Bleeding manifestations showed
no signiﬁcant associations with any potential predictors in the
model (data not shown).
Discussion
The aim of our study was to investigate the possible
association between PUUV RNA load and humoral immune
response with disease severity and from this, to gain further
knowledge of disease pathogenesis and possible treatment
alternatives. The majority of patients analysed had PUUV RNA
in plasma for over 1 week after disease onset. Interestingly,
the PUUV RNA load per se was not signiﬁcantly associated
with a more severe clinical outcome, suggested in previous
studies on HFRS and HCPS patients infected with other
hantaviruses [13–16]. Differences in virulence for different
hantaviruses could be an explanation: compared with other
hantaviruses causing HFRS and HCPS [13,14,16], we observed
a 10–100 times lower RNA load, suggesting that PUUV-
infected patients in general have lower levels of viraemia than
patients with other hantavirus infections. PUUV RNA was
detected in plasma for up to 3 weeks after disease onset;
however, the duration of PUUV RNA was not associated with
disease severity. There was a tendency for a higher viral load in
patients with moderate/severe illness during the ﬁrst 0–3 days,
although the sampling size was too small to ﬁnd a signiﬁcant
association to disease severity. From these ﬁndings, one could
speculate that antivirals may be beneﬁcial during the ﬁrst few
days after disease onset. The immune response has also been
implicated in the pathogenesis of hantavirus infections [1,2].
Accordingly, we found that higher WBC counts and especially
higher neutrophils were signiﬁcantly associated with more
severe disease.
Importantly, a low IgG response in the admission sample was
signiﬁcantly associated with disease severity. These ﬁndings are
supported by previous studies on patients infected with Sin
Nombre virus, showing association between low IgG titres
[19,20] and neutralizing antibodies [19] in severe disease. In
our study, one limitation was that neutralizing antibodies were
not analysed. We detected an inverse association between
hantavirus-speciﬁc IgG and IgA antibody titres and viral load, as
previously indicated for IgG [13,24] and salivary IgA [25].
However, in contrast to IgG titres, we did not observe any
association with disease severity for IgA and IgM titres. Our
data imply the importance of anti-PUUV-speciﬁc IgG antibodies
for virus clearance and protection against severe disease. It has
(a) (b) (c)
FIG. 2. Kinetics of Puumala hantavirus (PUUV) -speciﬁc humoral immune response. Each patient’s ﬁrst available serum sample is represented by a
dot. Antibody titres were signiﬁcantly (p <0.05) higher in late samples then in early samples, r, r² and p-value were calculated using linear regression
(log10 value of the titre). Moderate/severe patient samples are marked by red squares. (No samples were collected day 10–13).
TABLE 3. Regression analysis of predictors for moderate/
severe disease
Univariate analysis Multivariate analysis
Odds
ratio 95% CI
Odds
ratio 95% CI
Age 1.047* 1.004–1.092 1.029 0.980–1.080
Sex 1.000 0.334–2.991 – –
PUUV RNA levela
in plasma
1.099 0.816–1.479 – –
PUUV-speciﬁc IgM
titrea in serum
1.167 0.527–2.582 – –
PUUV-speciﬁc IgA
titrea in serum
1.042 0.579–1.874 – –
PUUV-speciﬁc IgG
titrea in serum
0.588* 0.376–0.920 0.442** 0.245–0.798
White blood cell countb 1.369*** 1.145–1.639 1.418*** 1.168–1.722
Day of disease when the
sample was collected
0.914c 0.755–1.107c – –
0.916d 0.703–1.194d – –
0.901e 0.694–1.171e – –
Levels were measured in each patient’s ﬁrst available sample.
Bold text indicate signiﬁcance, *p <0.05 **p <0.01 ***p <0.001.
aLog scale (10 log).
bScale: 1 unit = 1 9 109/L.
cPlasma sample for Puumala hantavirus (PUUV) RNA level. Subdivision into time
intervals 0–3, 4–7 and 8–11 days was not signiﬁcantly associated with moderate/
severe illness (p 0.12, p 0.454 and p 0.747, respectively). Conﬁdence intervals not
applicable because of small samples sizes.
dSerum sample for antibody titre.
eSerum sample for white blood cell count.
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previously been shown that case-fatality rate increases with age
during HFRS caused by PUUV and Seoul virus [26,27]. In line
with these observations, we here show that high age is a risk
factor for severe HFRS caused by PUUV infection. Female sex
has been reported to be a risk factor for lethal outcome of
HFRS caused by Seoul virus [27]. However, we did not ﬁnd an
association between sex and disease severity or hospitalization
frequency for PUUV-caused HFRS.
Hantaviruses in the Americas cause cardiac and respiratory
symptoms, features of HCPS. In our study of patients withHFRS,
respiratory symptoms were frequently observed, supporting
the similarities to HCPS [2,28]. We did not include these
symptoms as a criterion for severe disease, but we found that a
low PUUV-speciﬁc IgG response was associated with airway
symptoms and need of oxygen treatment in the HFRS patients.
A low IgG response against PUUV was associated with
moderate/severe disease. Previous studies in animal models
that mirror HFRS and HCPS have shown that serum containing
neutralizing antibodies can prevent disease development
[29,30]. Interestingly, in an unpublished ongoing clinical trial
in South America, patients with HCPS have been treated with
fresh plasma from survivors that contains high levels of
neutralizing antibodies. Preliminary data suggest a reduction in
mortality in these passively immunized patients with HCPS
(referred by Dolgin [5]).
In conclusion, our results suggest a relationship between a
strong speciﬁc IgG response and a favourable clinical outcome
of patients. Although further studies are needed, our results
support the use of passive immunization as a potential
treatment for HFRS/HCPS.
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